AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to AstraZeneca COPD drug tozorakimab cuts exacerbations in Phase III trials

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 8, 2026 7:50 AM EDT

Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds

Full results published in the New England Journal of Medicine and presented at the European Respiratory Society Congress 2026

Tozorakimab Biologics License Application accepted under Priority Review in US for patients with COPD

WILMINGTON, Del.--(BUSINESS WIRE)-- Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in reducing moderate and severe exacerbations in a broad population of patients with chronic... More